The Proceedings Of The 19Th International Conference On Chelation Held In London, United Kingdom: Major Changes In Iron Chelation Therapy In The Last 25 Years Using Deferiprone (L1) Has Resulted In The Complete Treatment Of Iron Overload

REFERENCES

• Hoffbrand AV, Bartlett AN, Veys PA, O’Connor NT, Kontoghiorghes GJ. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial. Lancet. 1989;2(8660):457.
   PubMed Web of Science ®Google Scholar
• Abstract Book. 1st International Conference on Chelators (ICOC) for the Treatment of Thalassemia and Other Diseases. London, United Kingdom. November 2–4, 1989.
   Google Scholar
• Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci (Elite Ed.). 2009;1:161–178.
   PubMedGoogle Scholar
• Abstract Book. 19th International Conference on Chelation (ICOC) for the Treatment of Thalassemia, Cancer and Other Diseases. London, United Kingdom. November 13–16, 2009.
   Google Scholar
• Kontoghiorghes GJ. The design of orally active iron chelators for the treatment of thalassaemia. Doctoral thesis, University of Essex, Colchester, UK. British Library Microfilm No. D66194/86. 1982:1–243.
   Google Scholar
• Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet. 1987;1(8545):1294–1295.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, . Effective chelation of iron in β thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J. 1987;295(6612):1509–1512.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1–2):41–47.
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466–475.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol. 2010;85(5):430–438.
   PubMed Web of Science ®Google Scholar
• Tefler P, Goen PG, Christou S, . Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980–2004. Haematologica. 2006;91(9):1187–1192.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, . A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876–1884.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B, . Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171–2179.
   PubMed Web of Science ®Google Scholar
• Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934–1936.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Kati M, Farmaki D, . Intensive chelation therapy in β-thalassemia and possible adverse cardiac effects of desferrioxamine. Int J Haematol. 2007;86(3):212–215.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Kolnagou A, Peng CT, Shah SV, Aessopos A. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf. 2010;9(2):201–206.
   PubMed Web of Science ®Google Scholar
• Boddaert N, Le Quan Sang KH, Rotig A, . Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood. 2007;110(1):401–408.
   PubMed Web of Science ®Google Scholar
• Rajapurkar MM, Alam MG, Bhattacharya A, Shah S. Novel treatment for diabetic nephropathy. J Am Soc Nephrol. 2007;18:329A.
   Google Scholar
• Rajapurkar MM, Beliga R, Shah S. Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol. 2007;18:57A–58A.
   Google Scholar
• Forni GL, Balocco M, Cremonesi L, Abbruzzese G, Parodi RC, Marchese R. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord. 2008;23(6):904–907.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr Med Chem. 2005;12(23):2663–2681.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin. 2008;32(6):608–615.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin. 2009;33(5):332–338.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes G J, Sheppard L. Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones. Inorg Chim Acta. 1987;136:L11–L12.
   Web of Science ®Google Scholar
• Morales NP, Yamanont P, Jirasomprasert T, . Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers. Int J Clin Pharmacol Ther. 2009;47(5):358–364.
   PubMed Web of Science ®Google Scholar